DelveInsight's Rheumatoid Arthritis Pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Researchers at the University of California Davis Comprehensive Cancer Center have uncovered an evolutionary change that may ...

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers—including intrahepatic cholangiocarcinoma, endometrial ...

DelveInsight’s Metastatic Prostate Cancer Pipeline report depicts a robust space with 80+ active players working to develop ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

A little-known molecule may be the key to treating aggressive cancer that often strikes young people, a study from ...

T cells are a natural part of the immune system designed to fight infections and cancer, but in conditions like blood cancer, they may not be able to eliminate malignant cells, according to Dr.

HER2 tumor marker tests are used to determine whether breast cancer is HER2 positive or negative. A person is a candidate for ...

In the Phase 2 MINDFuL trial of XProTM in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat ...

Eight researchers specializing in adult oncology from Fred Hutch Cancer Center and the University of Washington have been ...

In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) ...

In the Phase 2 MINDFuL trial of XPro in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary co ...